Germline BRCA-mutated metastatic breast cancer with positive hormone receptor

被引：0
|
作者：
Michela Palleschi
Maria Laura Iaia
Chiara Casadei
机构：
[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：265 / 266
页数：1
相关论文
共 50 条
  • [41] Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
    Lambertini, M.
    Goldrat, O.
    Ferreira, A. R.
    Dechene, J.
    Azim, H. A., Jr.
    Desir, J.
    Delbaere, A.
    t'Kint de Roodenbeke, M. -D.
    de Azambuja, E.
    Ignatiadis, M.
    Demeestere, I.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 237 - 243
  • [42] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
    Cruz, C.
    Castroviejo-Bermejo, M.
    Gutierrez-Enriquez, S.
    Llop-Guevara, A.
    Ibrahim, Y. H.
    Gris-Oliver, A.
    Bonache, S.
    Morancho, B.
    Bruna, A.
    Rueda, O. M.
    Lai, Z.
    Polanska, U. M.
    Jones, G. N.
    Kristel, P.
    de Bustos, L.
    Guzman, M.
    Rodriguez, O.
    Grueso, J.
    Montalban, G.
    Caratu, G.
    Mancuso, F.
    Fasani, R.
    Jimenez, J.
    Howat, W. J.
    Dougherty, B.
    Vivancos, A.
    Nuciforo, P.
    Serres-Creixams, X.
    Rubio, I. T.
    Oaknin, A.
    Cadogan, E.
    Barrett, J. C.
    Caldas, C.
    Baselga, J.
    Saura, C.
    Cortes, J.
    Arribas, J.
    Jonkers, J.
    Diez, O.
    O'Connor, M. J.
    Balmana, J.
    Serra, V
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1203 - 1210
  • [43] Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR plus ) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
    Eiermann, Wolfgang
    Rugo, Hope S.
    Diab, Sami
    Ettl, Johannes
    Hurvitz, Sara A.
    Goncalves, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06): : 523 - 533
  • [45] Incidence of germline BRCA1-and BRCA2-mutated breast cancer in the US
    Kim, R.
    Peterson, A.
    Isherwood, A.
    Uppal, H.
    Barlev, A.
    CANCER RESEARCH, 2017, 77
  • [46] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
    Spring, L. M.
    Han, H.
    Hamilton, E.
    Irie, H.
    Santa-Maria, C. A.
    Reeves, J.
    Pan, P.
    Shan, M.
    Tang, Y.
    Graham, J. R.
    Hazard, S.
    Ellisen, L. W.
    Isakoff, S. J.
    BREAST, 2021, 56 : S55 - S56
  • [47] The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
    Wibisono, M. G.
    Wibisono, M. H.
    Sabran, M. Z.
    Wibisono, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1404
  • [48] Fulvestrant in management of hormone receptor-positive metastatic breast cancer
    Shafaee, Maryam Nemati
    Ellis, Matthew James
    FUTURE ONCOLOGY, 2018, 14 (18) : 1789 - 1800
  • [49] New approaches for hormone-receptor positive metastatic breast cancer
    Thanopoulou E.
    Johnston S.R.D.
    Current Breast Cancer Reports, 2013, 5 (4) : 309 - 320
  • [50] Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer
    Sg, Nithin
    Gogia, Ajay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08)
12345